Male Reproductive Cancers
African Americans have a 60% higher incidence of prostate cancer and are about 2 times more likely to die from the disease.
Seven hundred and fifty-one patients were assigned to the 70.2 Gy group and 748 were assigned to the 79.2 Gy group. The median follow-up was 8.4 years.
A previous study showed that using 5-ARIs to treat benign prostate hyperplasia decreased the risk of low-grade PCa.
Recommendations about population-wide PSA screening are mixed, with some studies suggesting that the potential benefits of early diagnosis are outweighed by overtreatment.
A study could not determine whether one liquid biopsy panel is more accurate than another overall.
Apalutamide is also the first agent to be approved for meeting the primary endpoint of metastasis-free survival.
New diagnostic and therapeutic tools are in development to inform the management of advanced and metastatic disease.
In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.
It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.
Researchers randomly assigned 1401 men with M0 CRPC undergoing ADT to receive enzalutamide 160 mg or placebo.
It is unestablished whether daily or weekly IGRT is optimal for patients with N0 localized prostate cancer.
A significant reduction in prostate cancer-specific mortality — the primary outcome — was observed among patients who received 18 months of AS.
AS is recommended for men with low-risk PCa; this option can mitigate treatment-related reduction in quality of life.
Previous studies demonstrated that patients with metastatic hormone-sensitive prostate cancer treated with docetaxel have prolonged overall survival.
Hypofractionated radiotherapy's role in postoperative settings remains unclear and awaits outcomes from ongoing studies.
Researchers accessed the National Prostate Cancer Register of Sweden to evaluate the treatment strategies and outcomes for 74,643 patients with Pca.
Abiraterone acetate, prednisone, and ADT improve outcomes in the metastatic castration-naive setting, though whether this combination improves PROs and HRQoL was previously unknown.
Researchers assessed CTC and PSA response endpoints in 6081 patients enrolled in 1 of 5 randomized phase 3 studies.
Apalutamide is a next-generation, orally administered inhibitor of the androgen receptor.
Up to 20% of patients with prostate cancer treated with radiation therapy — external or internal via brachytherapy — will develop radiation colitis.
More evidence may be needed to understand the safety and efficacy of radium-223 in combination with abiraterone or enzalutamide.
Socioeconomic status, including education and income level, appears to be tied to prostate-specific antigen test results and prostate cancer treatment and survival, but the exact nature of these associations is not yet clear.
For this study, investigators tapped into the Surveillance, Epidemiology, and End Results database to identify and review data from 155,524 men younger than 65 years who were diagnosed with prostate cancer.
Custirsen inhibits clusterin production, which is associated with chemotherapy resistance; previous study suggested that custirsen may improve progression-free survival in this setting.
Researchers evaluated data from 14,715 men with PCa from the Taiwan National Health Insurance Research Database, of whom 24.3% underwent bilateral orchiectomies and 75.7% received GnRHa therapy.
Cancer Therapy Advisor asked Dr David Graham and Dr Alexander Kutikov about the state of the science of circulating tumor cell testing in prostate cancer, as well as this emerging field's potential clinical applications.
Androgen receptor-targeting agents are being used with increasing frequency in patients with mCRPC because of their efficacy, favorable safety profile, and ease of administration.
Researchers tracked the outcomes of 118,543 Swedish patients diagnosed with PCa over a median period of 8.3 years; patients were stratified by characteristics and treatment type.
The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma